The IPO is a combination of a fresh issue of shares aggregating Rs 353.4 crore and an Offer For Sale (OFS) of 1.12 crore shares by the selling shareholders.As part of the OFS, promoters – Investcorp Private Equity Fund II, Healthcare Parent, Investcorp Growth Opportunity Fund, Edoras Investment Holdings Pte. Ltd – along with other shareholders – Investcorp India Private Equity Opportunity, International Finance Corporation and 360 One Special Opportunities Funds – will sell shares.
Of the new outlay, the company proposes to use Rs 129.1 crore for opening new dialysis clinics in India; Rs 136 crore payment of debts; and the balance for general corporate purposes. Founded in 2009, NephroPlus had a global network of 519 clinics as of September 30, 2025, including 51 clinics in the Philippines, Uzbekistan and Nepal.
In FY2024, it also expanded into the Kingdom of Saudi Arabia (KSA) market by forming a joint venture with Arabian International Healthcare Holding Company, an Al Faisaliah Group company.
In addition, the 165-bed dialysis clinic in Tashkent, Uzbekistan is the largest dialysis clinic in the world.
NephroPlus is also the most widely distributed dialysis network in India as of September 2025, with an extensive pan-India network of clinics in 288 cities, spanning 21 states and 4 Union Territories. Of these, 77 percent of the clinics are in tier II and tier III cities and towns.
Financially, NephroPlus posted revenue from operations of Rs 756 crore and profit after tax of Rs 67 crore in FY25.
ICICI Securities, Ambit, IIFL Capital Services and Nomura Financial Advisory and Securities (India) Private Ltd are the lead managers of the issue.
#NephroPlus #public #December #eyes #353cr #release